MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer-Reference-Cited by-同舟云学术

MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer

Published:2020-12 Issue:4 Volume:19 Page:311-318.e1
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Camera Silvia,Deleporte Amélie,Bregni Giacomo,Trevisi Elena,Pretta Andrea,Telli Tugba Akin,Polastro Laura,Gombos Andrea,Kayumba Aline,Ameye Lieveke,Piccart-Gebhart Martine,Awada Ahmad,Sclafani Francesco,Hendlisz Alain

Funder

Sanofi

Amgen

AstraZeneca

Lilly

MSD

Novartis

Pfizer

Radius

Roche-Genentech

Servier

Synthon

Mylan

Roche

Bayer

BMS

Ipsen

Leo Pharma

Merck

Teva Pharma

Sirtex

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference42 articles.

1. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

2. Trends and challenges in tumor anti-angiogenic therapies;Jászai;Cells,2019

3. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis;Abdel-Qadir;Cancer Treat Rev,2017

4. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients;Totzeck;Eur J Prev Cardiol,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma;Cancers;2024-04-26

2. Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer;European Journal of Nuclear Medicine and Molecular Imaging;2023-12-23

3. A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer;Thoracic Cancer;2023-07-04

4. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice;Frontiers in Oncology;2021-05-10